Drugmakers Build to Buy

If you build it, they will buy it (especially if they told you what to build to begin with).

Quite a few big biotechs and pharmaceutical companies have called on venture capital firms to help them develop companies and compounds that they can turnaround and purchase once the drugs are developed further..

Biogen Idec recently hooked up with Atlas Ventures, contributing $17 million to help fund the VC's development of Ataxion with an option to purchase the company after phase one work is complete.

Celgene teamed up with Versant Ventures on a biotech incubator called Blueline Biosciences to develop compounds coming out of academic research in Ontario, Canada.

GlaxoSmithKline signed a deal last year with Avalon Ventures to fund as many as 10 biotech start-ups with as much as $465 million. In exchange, Glaxo has first rights on buying the new companies.

Not every large company is building with the expressed intent to buy the start-up though. Johnson & Johnson's Jansen Pharmaceuticals has a no-strings-attached incubator where start-ups pay rent and use shared equipment. While the incubator start-ups don't have to sign a deal to be purchased later, Johnson & Johnson hopes that being familiar with the companies working on its campus will help the health-care giant offer a fair price for the biotechs should they chose to sell.

In the video below, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss the trend and how it might be good for large drug companies, but bad for investors who prefer to invest in smaller biotechs.

Identifying innovation is the key
The key to getting market crushing returns is identifying companies that are breaking all the rules. Fool co-founder David Gardner and his team have a new free report that identifies six picks for ultimate growth. Click here now for your free access.

The article Drugmakers Build to Buy originally appeared on Fool.com.

Brian Orelli has no position in any stocks mentioned. Max Macaluso owns shares of Celgene. The Motley Fool recommends Celgene and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story